Anzeige
Mehr »
Login
Montag, 24.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
KI-Wunder? Diese Aktie verachtfacht sich nach Deepseek R1-Integration!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C5G6 | ISIN: DK0061670205 | Ticker-Symbol: N/A
1-Jahres-Chart
BRAIN+ A/S Chart 1 Jahr
5-Tage-Chart
BRAIN+ A/S 5-Tage-Chart

Aktuelle News zur BRAIN+ A/S Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09:18Brain+ A/S - reduction of share capital by reducing face value per share38The nominal share capital of Brain+ A/S will be reduced as of 26 February 2025 by reducing the face value of the company's shares from DKK 0.08 to DKK 0.01. Name: Brain+ ISIN: DK0061670205 Short...
► Artikel lesen
12.02.Brain+ A/S: Brain+ A/S - Minutes of Extraordinary General Meeting45Copenhagen, Denmark, 12 February 2025 - Brain+ A/S (Nasdaq First North: BRAINP) Today at 08:00 CEST, an Extraordinary General Meeting was held in Brain+ A/S ("Brain+" or "the Company"). A total of...
► Artikel lesen
30.01.BRAIN+ A/S: Invitation to Investor Webinar to update on sales outlook, restructuring and secured funding4
28.01.BRAIN+ A/S: Brain+ A/S - Notice of Extraordinary General Meeting1
22.01.Brain+ A/S: Brain+ restructures to reduce OPEX by 35%, maintaining €1M ARR target for end 2025 and now expecting break-even by mid-2026, and announces 50% secured intended Rights Issue78Copenhagen, Denmark, 22 January 2025 - Brain+ A/S (Nasdaq First North: BRAINP)Brain+ A/S ("Brain+" or the "Company") announces that today, its Board of Directors has decided to carry out a rights issue...
► Artikel lesen
31.12.24BRAIN A/S: Brain+ announces change of Certified Advisor2
BRAIN+ A/S Aktie jetzt für 0€ handeln
10.12.24BRAIN A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status2
05.12.24BRAIN A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality4
01.11.24BRAIN A/S: Brain+ closes new Danish municipality sales contract on Ayla - your CST Assistant1
21.10.24BRAIN A/S: Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy1
11.10.24BRAIN A/S: Brain+ unveils new visual brand and website to elevate its Ayla Dementia Care solutions1
07.10.24BRAIN A/S: Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue1
02.10.24BRAIN A/S: Brain+ launches Ayla - your CST Assistant into the UK dementia market1
01.10.24BRAIN A/S: Brain+ announces the outcome of its series TO 4 warrant exercise and the decision to carry out a directed share issue to cover guarantor subscriptions2
25.09.24BRAIN A/S: Brain+ confirms imminent commercial launch of Ayla - your CST Assistant as a medical device in the UK3
23.09.24BRAIN A/S: Brain+ informs of three product releases planned for 2025 and introduces a platform renaming as part of its UK commercialization2
20.09.24BRAIN A/S: Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4%2
17.09.24BRAIN A/S: Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 41
13.09.24BRAIN A/S: Brain+ is set to deliver on an ambitious UK commercial plan to reach recurring revenue of DKK 7-8 million by 2025 and DKK 25-27 million by 20271
13.09.24BRAIN A/S: Brain+ A/S announces the exercise price for its warrants of series TO 41
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1